FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515706651> ?p ?o ?g. }

• W2515706651 endingPage "1384" @default.
• W2515706651 startingPage "1377" @default.
• W2515706651 abstract "BackgroundIdentification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the effectiveness of different vaccine strategies to block virus shedding. We used samples from a clinical trial of different vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specific IgA in stools.MethodsIn the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-specific IgA were measured in stool after a monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all participants.Findings210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants receiving bOPV (p<0·0001) and 53 of 87 infants receiving bOPV–IPV (p<0·0001). Mucosal type 2 neutralisation and type-specific IgA were noted primarily in response to tOPV. An inverse correlation was noted between virus shedding and both serum type 2 neutralisation at challenge (p<0·0001) and mucosal type 2 neutralisation at challenge (p<0·0001).InterpretationMucosal type-2-specific antibodies can be measured in stool and develop in response to receipt of OPV type 2 either in the primary vaccine series or at challenge. These mucosal antibodies influence the amount of virus that is shed in an established infection.FundingBill & Melinda Gates Foundation." @default.
• W2515706651 created "2016-09-16" @default.
• W2515706651 creator A5002707102 @default.
• W2515706651 creator A5010655685 @default.
• W2515706651 creator A5014755332 @default.
• W2515706651 creator A5020311779 @default.
• W2515706651 creator A5025701158 @default.
• W2515706651 creator A5032859825 @default.
• W2515706651 creator A5034976745 @default.
• W2515706651 creator A5063476083 @default.
• W2515706651 creator A5066233901 @default.
• W2515706651 creator A5071990559 @default.
• W2515706651 creator A5088186295 @default.
• W2515706651 creator A5091135056 @default.
• W2515706651 date "2016-12-01" @default.
• W2515706651 modified "2023-10-12" @default.
• W2515706651 title "Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants" @default.
• W2515706651 cites W113637594 @default.
• W2515706651 cites W1659618301 @default.
• W2515706651 cites W1759712413 @default.
• W2515706651 cites W1843762508 @default.
• W2515706651 cites W1971110767 @default.
• W2515706651 cites W1986427539 @default.
• W2515706651 cites W2023922148 @default.
• W2515706651 cites W2031551277 @default.
• W2515706651 cites W2099420572 @default.
• W2515706651 cites W2102060315 @default.
• W2515706651 cites W2103358447 @default.
• W2515706651 cites W2109715645 @default.
• W2515706651 cites W2111091655 @default.
• W2515706651 cites W2111737459 @default.
• W2515706651 cites W2114361018 @default.
• W2515706651 cites W2139798676 @default.
• W2515706651 cites W2149302911 @default.
• W2515706651 cites W2155116147 @default.
• W2515706651 cites W2163308641 @default.
• W2515706651 cites W2196133620 @default.
• W2515706651 cites W2217538693 @default.
• W2515706651 cites W2335890187 @default.
• W2515706651 cites W2338519972 @default.
• W2515706651 cites W2396524001 @default.
• W2515706651 cites W4231125505 @default.
• W2515706651 cites W4384466965 @default.
• W2515706651 doi "https://doi.org/10.1016/s1473-3099(16)30169-4" @default.
• W2515706651 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5611465" @default.
• W2515706651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27638357" @default.
• W2515706651 hasPublicationYear "2016" @default.
• W2515706651 type Work @default.
• W2515706651 sameAs 2515706651 @default.
• W2515706651 citedByCount "46" @default.
• W2515706651 countsByYear W25157066512016 @default.
• W2515706651 countsByYear W25157066512017 @default.
• W2515706651 countsByYear W25157066512018 @default.
• W2515706651 countsByYear W25157066512019 @default.
• W2515706651 countsByYear W25157066512020 @default.
• W2515706651 countsByYear W25157066512021 @default.
• W2515706651 countsByYear W25157066512022 @default.
• W2515706651 countsByYear W25157066512023 @default.
• W2515706651 crossrefType "journal-article" @default.
• W2515706651 hasAuthorship W2515706651A5002707102 @default.
• W2515706651 hasAuthorship W2515706651A5010655685 @default.
• W2515706651 hasAuthorship W2515706651A5014755332 @default.
• W2515706651 hasAuthorship W2515706651A5020311779 @default.
• W2515706651 hasAuthorship W2515706651A5025701158 @default.
• W2515706651 hasAuthorship W2515706651A5032859825 @default.
• W2515706651 hasAuthorship W2515706651A5034976745 @default.
• W2515706651 hasAuthorship W2515706651A5063476083 @default.
• W2515706651 hasAuthorship W2515706651A5066233901 @default.
• W2515706651 hasAuthorship W2515706651A5071990559 @default.
• W2515706651 hasAuthorship W2515706651A5088186295 @default.
• W2515706651 hasAuthorship W2515706651A5091135056 @default.
• W2515706651 hasBestOaLocation W25157066511 @default.
• W2515706651 hasConcept C126322002 @default.
• W2515706651 hasConcept C151492266 @default.
• W2515706651 hasConcept C159047783 @default.
• W2515706651 hasConcept C159654299 @default.
• W2515706651 hasConcept C168563851 @default.
• W2515706651 hasConcept C203014093 @default.
• W2515706651 hasConcept C22070199 @default.
• W2515706651 hasConcept C2522874641 @default.
• W2515706651 hasConcept C2779102806 @default.
• W2515706651 hasConcept C2779341262 @default.
• W2515706651 hasConcept C2779631682 @default.
• W2515706651 hasConcept C2780898057 @default.
• W2515706651 hasConcept C2908689829 @default.
• W2515706651 hasConcept C4870876 @default.
• W2515706651 hasConcept C71924100 @default.
• W2515706651 hasConcept C8891405 @default.
• W2515706651 hasConceptScore W2515706651C126322002 @default.
• W2515706651 hasConceptScore W2515706651C151492266 @default.
• W2515706651 hasConceptScore W2515706651C159047783 @default.
• W2515706651 hasConceptScore W2515706651C159654299 @default.
• W2515706651 hasConceptScore W2515706651C168563851 @default.
• W2515706651 hasConceptScore W2515706651C203014093 @default.
• W2515706651 hasConceptScore W2515706651C22070199 @default.
• W2515706651 hasConceptScore W2515706651C2522874641 @default.
• W2515706651 hasConceptScore W2515706651C2779102806 @default.
• W2515706651 hasConceptScore W2515706651C2779341262 @default.

• next